Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Allan M Johansen

Showing results (1-10 of 5) with videos related to

Pageof 1
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 25, 2024
TGFβ in Pancreas and Colorectal Cancer: Opportunities to Overcome Therapeutic ResistanceAllan M Johansen, Steven D Forsythe, Callum T McGrath, et al.
The FEBS Journal|October 19, 2011
Rate, affinity and calcium dependence of nitric oxide synthase isoform binding to the primary physiological regulator calmodulinJonathan L McMurry, Carol A Chrestensen, Israel M Scott, et al.
NPJ Breast Cancer|July 19, 2022
TGFBR1*6A as a modifier of breast cancer risk and progression: advances and future prospectsKojo Agyemang, Allan M Johansen, Grayson W Barker, et al.
Cancer Communications (London, England)|June 11, 2026
<i>TGFBR1</i>*6A and Risk for Colorectal CancerAllan M Johansen, Julie T Ziegler, Kojo Agyemang, et al.
Biorxiv : the Preprint Server for Biology|December 15, 2025
Co-targeting KRAS and Exportin1 as an effective therapeutic strategy for KRASG12D mutant pancreatic ductal adenocarcinomaHusain Yar Khan, Mohammed Najeeb Al Hallak, Amro Aboukameel, et al.
Pageof 1

Showing results (1-10 of 5) with videos related to

Sort By:
Pageof 1
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 25, 2024
TGFβ in Pancreas and Colorectal Cancer: Opportunities to Overcome Therapeutic ResistanceAllan M Johansen, Steven D Forsythe, Callum T McGrath, et al.
The FEBS Journal|October 19, 2011
Rate, affinity and calcium dependence of nitric oxide synthase isoform binding to the primary physiological regulator calmodulinJonathan L McMurry, Carol A Chrestensen, Israel M Scott, et al.
NPJ Breast Cancer|July 19, 2022
TGFBR1*6A as a modifier of breast cancer risk and progression: advances and future prospectsKojo Agyemang, Allan M Johansen, Grayson W Barker, et al.
Cancer Communications (London, England)|June 11, 2026
<i>TGFBR1</i>*6A and Risk for Colorectal CancerAllan M Johansen, Julie T Ziegler, Kojo Agyemang, et al.
Biorxiv : the Preprint Server for Biology|December 15, 2025
Co-targeting KRAS and Exportin1 as an effective therapeutic strategy for KRASG12D mutant pancreatic ductal adenocarcinomaHusain Yar Khan, Mohammed Najeeb Al Hallak, Amro Aboukameel, et al.
Pageof 1